Brand & Manufacturer VerifiedFrance
Virbac S.A.
Virbac
Virbac is a dedicated animal health pharmaceutical company founded by a veterinarian in 1968, operating on the principle "by a veterinarian, for veterinarians." Headquartered in Carros, Provence-Alpes-Côte d'Azur, France, Virbac generated EUR 1.465 billion (~USD 1.6 billion) in 2025 revenue (organic growth of 7.9%), employing 6,400 employees across 12 production sites in 12 countries. Companion animal products now constitute 62% of total sales, with dental care, dermatology, and specialty endocrine therapeutics (bolstered by the landmark €107.8M Thyronorm acquisition) driving premium pricing in North American and European markets.
Strengths:
• Companion Animal Purity: 62% of revenue from companion animals, with particularly strong positions in dental care (VeggieDent, Enzadent) and dermatology (Cortavance, Allerderm)
• Strategic Asia-Pacific Expansion: €280M acquisition of Japanese animal health company Sasaeah in 2025 added manufacturing facilities in Japan and Vietnam, instantly establishing APAC production base
• Regional Manufacturing Autonomy: 12 production sites across 12 countries, including a recently initiated viral antigen manufacturing plant in Montevideo, Uruguay—the first of its kind in Latin America
• Veterinarian-Centric Heritage: Founded by a veterinarian, the company maintains deep clinical credibility and loyalty within the global veterinary community
• Capital Discipline: €102M in 2025 capital expenditure focused on solving supply chain bottlenecks and supporting future volume growth in premium therapeutic categories
Weaknesses:
• Currency Exposure: Significant revenue from Latin America, Asia-Pacific, and Middle East/Africa creates recurring currency translation headwinds (noted in 2025 results)
• Mid-Tier Revenue Scale: At ~$1.6B, Virbac operates in a competitive middle tier where R&D budgets are materially smaller than the Big Four, constraining pipeline breadth
• Integration Risk: The recent Sasaeah acquisition introduces operational complexity across Japanese, Vietnamese, and existing French manufacturing sites requiring multi-year integration effortsRead MoreShow Less
Strengths:
• Companion Animal Purity: 62% of revenue from companion animals, with particularly strong positions in dental care (VeggieDent, Enzadent) and dermatology (Cortavance, Allerderm)
• Strategic Asia-Pacific Expansion: €280M acquisition of Japanese animal health company Sasaeah in 2025 added manufacturing facilities in Japan and Vietnam, instantly establishing APAC production base
• Regional Manufacturing Autonomy: 12 production sites across 12 countries, including a recently initiated viral antigen manufacturing plant in Montevideo, Uruguay—the first of its kind in Latin America
• Veterinarian-Centric Heritage: Founded by a veterinarian, the company maintains deep clinical credibility and loyalty within the global veterinary community
• Capital Discipline: €102M in 2025 capital expenditure focused on solving supply chain bottlenecks and supporting future volume growth in premium therapeutic categories
Weaknesses:
• Currency Exposure: Significant revenue from Latin America, Asia-Pacific, and Middle East/Africa creates recurring currency translation headwinds (noted in 2025 results)
• Mid-Tier Revenue Scale: At ~$1.6B, Virbac operates in a competitive middle tier where R&D budgets are materially smaller than the Big Four, constraining pipeline breadth
• Integration Risk: The recent Sasaeah acquisition introduces operational complexity across Japanese, Vietnamese, and existing French manufacturing sites requiring multi-year integration efforts
FranceFounded 19686,400EUR$1.5 B12 production sites across 12… / 100
Listed onEURONEXTVIRP
Listed market data
VIRP · Euronext · weeklyHistory →- Market cap
- $3.2 B
- Share price
- ≈ EUR 378.52
- 1Y change
- -2.6%
- Recent change
- -0.3%
- Since first close
- +915.7%
- Revenue (TTM)
- $1.7 B
10-22 → 10-23
from 1992-07
Revenue FY 2025 · updated 2026-10-23Source ↗
Financial history
Full market historyMonthCloseMarket capChange
- 2026-10EUR 337.00$2.8 B0.0%
- 2026-09EUR 337.00$2.8 B+8.2%
- 2026-08EUR 311.50$2.6 B-3.4%
- 2026-07EUR 322.50$2.7 B-4.4%
- 2026-06EUR 337.50$2.8 B+1.5%
- 2026-05EUR 332.50$2.8 B-7.3%
- 2026-04EUR 358.50$3 B-3.5%
- 2026-03EUR 371.50$3.1 B+4.8%
- 2026-02EUR 354.50$3 B-4.2%
- 2026-01EUR 370.00$3.1 B+5.3%
- 2025-12EUR 351.50$2.9 B-1.7%
- 2025-11EUR 357.50$3 B—
Monthly closes · 2025-11 – 2026-10 · Full market history
In the press
All coverage →5 latest headlines- Virbac targets upper guidance range for Virbac stock - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Virbac: sales up 7.9% over first nine months, targeting upper guidance range - Idéal Investisseurwww.ideal-investisseur.fr2026-10-20
- Virbac SA (VIRP.PA) Stock Price, News, Quote & History - Yahoo! Finance Canadaca.finance.yahoo.com2026-10-19
- Virbac targets the high end of its guidance range - www.marketscreener.comwww.marketscreener.com2026-10-19
- France's Virbac Q3 revenue rises on strength in Both Companion Animal, Farm Animal segments - TradingViewwww.tradingview.com2026-10-19
Headlines aggregated from public feeds. Sentiment tags are keyword-based, not editorial judgement.
Virbac is a dedicated animal health pharmaceutical company founded by a veterinarian in 1968, operating on the principle "by a veterinarian, for veterinarians." The company's industrial footprint spans 12 manufacturing sites across 12 countries, strategically distributed to ensure regional supply chain resilience. Its Carros, France headquarters houses advanced vaccine and sterile injectable production.
In Latin America, its Montevideo, Uruguay facility has recently broken ground on a dedicated viral antigen manufacturing plant—a landmark investment that gives Virbac rare in-region core vaccine antigen production capability. The company completed its landmark €280 million acquisition of Japanese animal health company Sasaeah in 2025, adding manufacturing facilities in Japan and Vietnam, plus 500+ specialized employees, instantly establishing a significant Asia-Pacific production base. Companion animal products now constitute 62% of total sales.
In Latin America, its Montevideo, Uruguay facility has recently broken ground on a dedicated viral antigen manufacturing plant—a landmark investment that gives Virbac rare in-region core vaccine antigen production capability. The company completed its landmark €280 million acquisition of Japanese animal health company Sasaeah in 2025, adding manufacturing facilities in Japan and Vietnam, plus 500+ specialized employees, instantly establishing a significant Asia-Pacific production base. Companion animal products now constitute 62% of total sales.
Companion Animal Portfolio — Core Business
• Dental Care: VeggieDent / Enzadent
• Dermatology: Cortavance / Allerderm
• Parasiticides: Effipro / Milbemax
• Endocrinology: Thyronorm post-acquisition
• Vaccines: Canigen / Feligen
• Pet Nutrition
• Dental Care: VeggieDent / Enzadent
• Dermatology: Cortavance / Allerderm
• Parasiticides: Effipro / Milbemax
• Endocrinology: Thyronorm post-acquisition
• Vaccines: Canigen / Feligen
• Pet Nutrition
Quick Facts
Headquarters
Carros, Provence-Alpes-Côte d'Azur, France
Founded
1968
Employees
6,400
Revenue
EUR$1.5 B (~USD$1.6 B, 2025)
Market cap
$3.2 B
Factories
12 production sites across 12 countries
Presence
Products sold in 100+ countries, subsidiaries in 35 countries
Listing
Euronext Paris: VIRP
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $616 B
- Allergan Aesthetics· $504 B
- AbbVie Inc.· $504 B
- F. Hoffmann-La Roche AG· $372 B
- Merck Animal Health· $360 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website Euronext Paris: VIRP , Virbac Corporate Website
Wikipedia — Virbac
Euronext — Virbac (VIRP)